The treatment plan for Crohn’s disease now focuses on a treat-to-target approach where effectiveness is determined using specific treatment goals, particularly mucosal healing on endoscopy. In this touchIMMUNOLOGY interview, we speak with Dr Vipul Jairath (Western University, University Hospital, London, ON, Canada) to discuss the treat-to-target approach in Crohn’s disease and the unmet needs in this population.
The abstract entitled ‘A CLUSTER-RANDOMISED CONTROLLED TRIAL OF AN ENHANCED TREATMENT ALGORITHM FOR THE MANAGEMENT OF CROHN’S DISEASE: REACT-2’ (Abstract no: OP110) was presented at UEG Week, October 8 – 11, 2022.
Question:
- Could you give us a brief overview of the treat-to-target approach in Crohn’s disease and the unanswered questions regarding this approach? (0:23)
Disclosures: Vipul Jairath is a consultant for AbbVie, Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), Amgen, Applied Strategic, Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris, AstraZeneca, BioJamp. Celgene/BMS, Celltrion, Eli Lilly, Ferring, F. Hoffman-La Roche Ltd, Flagship Pioneering, Fresenius Kabi, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen, Organon (Merck), Landos BioPharma, Mylan, Pandion, Pendopharm, Pfizer, Protagonist Therapeutics, Reistone Biopharma, Roche, Sandoz, Second Genome, Takeda, Teva, Topivert, Ventyx Biosciences, Vividion Therapeutics. He is also a speaker’s bureau participant with Abbvie, Ferring, Galapagos, Janssen, Pfizer, Takeda.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of UEG Week 2022
Access more content on Gastroenterology here
